Humanized monoclonal antibodies, derived from fully human sequences or engineered to resemble human antibodies, have addressed critical challenges of immunogenicity seen with earlier antibody therapies.

Monoclonal antibodies (mAbs) are engineered molecules designed to target specific antigens, such as those on pathogens or diseased cells. When these antibodies bind to their targets, they can activate immune responses to eliminate the threat. Traditional mAb development relied on hybridomas derived from animal cells, but these antibodies often elicited immune responses when introduced into humans due to their non-human origin.

The AbDrop™ platform uses microfluidic technology to encapsulate individual plasma cells in droplets. This high-throughput approach enables researchers to screen millions of plasma B cells in a single day.Workflow Highlights:One Day: Millions of B cells screened for antibody-producing potential.&nb

Fully human antibodies, developed using human genes, are advancing antibody-based therapeutics. These antibodies reduce immunogenicity, improving patient safety and tolerance. Traditional methods, like humanized mice, require genetic modifications to produce human antibodies, often increasing comple

DOI:10.1007/s12033-024-01270-yFully human antibodies are sought after for therapeutic development due to their reduced risk of immunogenicity and superior compatibility with the human immune system. Innovations in this field are accelerating the discovery pipeline, enhancing specificity, affinity, a

Monoclonal antibodies (mAbs) are attractive therapeutic tools, being highly specific for their targets. However, immunogenicity, the potential of a therapeutic antibody to provoke an immune response, remains a risk.

Together with the Chinese Antibody Society, Biointron's latest webinar features Shun Zhou, Ph.D, the R&D Director at Cyagen

Image credit: Institute for ProteinIn the competitive landscape of antibody development, speed and precision are necessary. Traditional antibody discovery platforms—such as hybridoma and phage display—often have lengthytimelines to generate viable antibody candidates. However, Biointron’s A

Antibody discovery has undergone a transformation with advances in single B cell screening technologies. Biointron’s AbDrop™ platform leverages droplet-based microfluidics to access the full complement of antibody diversity, particularly within the complementary-determining regions

Monoclonal antibodies (mAbs) are useful therapeutics for targeted treatments in oncology, autoimmune disorders, and infectious diseases. Among the key distinctions in therapeutic mAbs are those labeled fully human and humanized. Both rely heavily on animal models (primarily mice) and genetic engineering techniques to achieve their therapeutic properties.

Biointron’s AbDrop platform revolutionizes antibody discovery by combining high-throughput screening with advanced microfluidic technology, enabling the identification of diverse and high-affinity antibodies. This process starts by isolating plasma B cells from immunized animals, encapsulating them in microdroplets to preserve natural heavy and light chain pairing, a critical factor for developing functional therapeutic antibodies.

Biointron’s AbDrop & Cyagen’s HUGO-Ab is a high-throughput fully human antibody discovery platform that combines microdroplet-based single B cell screening with transgenic mice. This combination accelerates the discovery and development of fully human antibodies, reducing the time from target identification to therapeutic candidate to just three months.

In the immune system, antibodies are responsible for identifying and neutralizing foreign invaders such as pathogens. They achieve this through the precise recognition of antigens, a process largely determined by the structure of their variable regions. Each antibody is composed of two types of protein chains: the heavy chain (HC) and the light chain (LC). These two chains form a highly specific pairing that is necessary for the antibody's ability to bind to its target antigen.

Discover how high-affinity antibodies enhance therapeutic precision, reduce side effects, and improve patient outcomes by targeting disease antigens effectively.

Discover why transgenic mice are essential for producing fully human antibodies. Learn how humanized immune systems improve antibody specificity & affinity in vivo.